358 related articles for article (PubMed ID: 37511177)
1. DNA Damage Repair Pathways in Prostate Cancer: A Narrative Review of Molecular Mechanisms, Emerging Biomarkers and Therapeutic Targets in Precision Oncology.
Grypari IM; Tzelepi V; Gyftopoulos K
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511177
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
Isaacsson Velho P; Qazi F; Hassan S; Carducci MA; Denmeade SR; Markowski MC; Thorek DL; DeWeese TL; Song DY; Tran PT; Eisenberger MA; Antonarakis ES
Eur Urol; 2019 Aug; 76(2):170-176. PubMed ID: 30293905
[TBL] [Abstract][Full Text] [Related]
3. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
Dariane C; Timsit MO
Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
[TBL] [Abstract][Full Text] [Related]
4. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
Annala M; Struss WJ; Warner EW; Beja K; Vandekerkhove G; Wong A; Khalaf D; Seppälä IL; So A; Lo G; Aggarwal R; Small EJ; Nykter M; Gleave ME; Chi KN; Wyatt AW
Eur Urol; 2017 Jul; 72(1):34-42. PubMed ID: 28259476
[TBL] [Abstract][Full Text] [Related]
5. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
[TBL] [Abstract][Full Text] [Related]
6. A transcriptomic model for homologous recombination deficiency in prostate cancer.
Weiner AB; Liu Y; McFarlane M; Bawa PS; Li EV; Zhao X; Li Z; Hammoud T; Hazime M; Karnes RJ; Davicioni E; Reichert ZR; Chinnaiyan AM; Lotan TL; Spratt DE; Schaeffer EM
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):659-665. PubMed ID: 34226663
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?
Slootbeek PHJ; Tolmeijer SH; Mehra N; Schalken JA
Crit Rev Clin Lab Sci; 2024 May; 61(3):178-204. PubMed ID: 37882463
[TBL] [Abstract][Full Text] [Related]
8. PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures.
McNevin CS; Cadoo K; Baird AM; Finn SP; McDermott R
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230674
[TBL] [Abstract][Full Text] [Related]
9. Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer.
van der Doelen MJ; Isaacsson Velho P; Slootbeek PHJ; Pamidimarri Naga S; Bormann M; van Helvert S; Kroeze LI; van Oort IM; Gerritsen WR; Antonarakis ES; Mehra N
Eur J Cancer; 2020 Sep; 136():16-24. PubMed ID: 32634759
[TBL] [Abstract][Full Text] [Related]
10. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
Castro E; Romero-Laorden N; Del Pozo A; Lozano R; Medina A; Puente J; Piulats JM; Lorente D; Saez MI; Morales-Barrera R; Gonzalez-Billalabeitia E; Cendón Y; García-Carbonero I; Borrega P; Mendez Vidal MJ; Montesa A; Nombela P; Fernández-Parra E; Gonzalez Del Alba A; Villa-Guzmán JC; Ibáñez K; Rodriguez-Vida A; Magraner-Pardo L; Perez-Valderrama B; Vallespín E; Gallardo E; Vazquez S; Pritchard CC; Lapunzina P; Olmos D
J Clin Oncol; 2019 Feb; 37(6):490-503. PubMed ID: 30625039
[TBL] [Abstract][Full Text] [Related]
11. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
[TBL] [Abstract][Full Text] [Related]
12. Olaparib for the treatment of metastatic prostate cancer.
Dror CM; Wyatt AW; Chi KN
Future Oncol; 2021 Jul; 17(19):2413-2429. PubMed ID: 33769071
[TBL] [Abstract][Full Text] [Related]
13. DNA repair defects in prostate cancer: impact for screening, prognostication and treatment.
Warner EW; Yip SM; Chi KN; Wyatt AW
BJU Int; 2019 May; 123(5):769-776. PubMed ID: 30281887
[TBL] [Abstract][Full Text] [Related]
14. Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine.
Marino F; Totaro A; Gandi C; Bientinesi R; Moretto S; Gavi F; Pierconti F; Iacovelli R; Bassi P; Sacco E
Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):655-664. PubMed ID: 36434163
[TBL] [Abstract][Full Text] [Related]
15. Multi-Gene Next-Generation Sequencing Panel for Analysis of
Maloberti T; De Leo A; Coluccelli S; Sanza V; Gruppioni E; Altimari A; Zagnoni S; Giunchi F; Vasuri F; Fiorentino M; Mollica V; Ferrari S; Miccoli S; Visani M; Turchetti D; Massari F; Tallini G; de Biase D
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240284
[TBL] [Abstract][Full Text] [Related]
16. DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.
Lu E; Thomas GV; Chen Y; Wyatt AW; Lloyd P; Youngren J; Quigley D; Bergan R; Bailey S; Beer TM; Feng FY; Small EJ; Alumkal JJ
J Natl Compr Canc Netw; 2018 Aug; 16(8):933-937. PubMed ID: 30099369
[No Abstract] [Full Text] [Related]
17. DNA Repair in Prostate Cancer: Biology and Clinical Implications.
Mateo J; Boysen G; Barbieri CE; Bryant HE; Castro E; Nelson PS; Olmos D; Pritchard CC; Rubin MA; de Bono JS
Eur Urol; 2017 Mar; 71(3):417-425. PubMed ID: 27590317
[TBL] [Abstract][Full Text] [Related]
18. Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
Fan L; Fei X; Zhu Y; Chi C; Pan J; Sha J; Xin Z; Gong Y; Du X; Wang Y; Dong B; Xue W
J Urol; 2021 Sep; 206(3):630-637. PubMed ID: 33904759
[TBL] [Abstract][Full Text] [Related]
19. Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer.
Kaur HB; Vidotto T; Mendes AA; Salles DC; Isaacs WB; Antonarakis ES; Lotan TL
Cancer Immunol Immunother; 2022 Apr; 71(4):943-951. PubMed ID: 34533610
[TBL] [Abstract][Full Text] [Related]
20. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
